NCT07529535 2026-04-17
A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase 1 Suspended
Clinical Trials
11 trialsNCT05938296 2025-11-19
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
Binhui Biopharmaceutical Co., Ltd.
Phase 1 Suspended
NCT05055518 2025-06-27
APL-102 Capsule in Patients With Advanced Solid Tumors
Apollomics Inc.
Phase 1 Suspended
NCT05571969 2025-05-07
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
Allarity Therapeutics
Phase 1 Suspended
NCT05416749 2024-11-20
A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Suspended
NCT03859752 2023-09-22
TR1801-ADC in Patients With Tumors That Express c-Met
Open Innovation Partners, Inc.
Phase 1 Suspended
NCT01627795 2018-04-18
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
Oshadi Drug Administration
Phase 1/2 Suspended
NCT01762410 2014-09-29
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
Piramal Enterprises Limited
Phase 1 Suspended
NCT01779336 2014-09-29
Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
Piramal Enterprises Limited
Phase 1 Suspended
NCT01604863 2012-11-01
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
GlaxoSmithKline
Phase 1 Suspended
NCT00591682 2008-03-26
MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
Metastatix, Inc.
Phase 1 Suspended